Ionis Pharmaceuticals (IONS) Current Deferred Revenue (2009 - 2026)

Ionis Pharmaceuticals' Current Deferred Revenue history runs 18 years deep, the most recent figure standing at $69.2 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 1509.28% year-over-year to $69.2 million; the TTM figure through Mar 2026 stood at $69.2 million (up 1509.28% YoY), while the FY2025 annual figure was $73.8 million, down 6.62% from the prior year.
• Current Deferred Revenue was $69.2 million for Q1 2026 at Ionis Pharmaceuticals, down from $73.8 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $204.8 million in Q3 2023 to a low of $4.3 million in Q1 2025.
• Historically, Current Deferred Revenue has averaged $94.1 million across 5 years, with a median of $91.4 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Current Deferred Revenue slumped 96.7% in 2025, then surged 1509.28% in 2026.
• A 5-year view of Current Deferred Revenue shows it stood at $90.6 million in 2022, then soared by 66.85% to $151.1 million in 2023, then plunged by 47.73% to $79.0 million in 2024, then dropped by 6.62% to $73.8 million in 2025, then dropped by 6.18% to $69.2 million in 2026.
• The last three Current Deferred Revenue figures came in at $69.2 million (Q1 2026), $73.8 million (Q4 2025), and $77.0 million (Q3 2025), per Business Quant data.